1,000+ Opportunities

Find the right grant

Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.

This listing may be outdated. Verify details at the official source before applying.

Find similar grants

ActiveRegeneron Pharmaceuticals · 2026

EYLEA4U Patient Assistance Program

Quick Facts

Agency: Regeneron Pharmaceuticals
Funding: Covers costs of EYLEA (aflibercept) injection
Deadline: Check Source
Status: Active
Eligibility: Patients who are uninsured, underinsured, or lack insurance coverage for EYLEA, are US residents, are enrolled in EYLEA4U, and show financial need. Eligible patients will be enrolled for up to 12 months.

About This Grant

EYLEA4U Patient Assistance Program is sponsored by Regeneron Pharmaceuticals. A comprehensive support program for eligible patients diagnosed with Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (Wet AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), and Retinopathy of Prematurity (ROP).

View Original RFP

Get alerted about grants like this

Save a search for “Regeneron Pharmaceuticals” or related topics and get emailed when new opportunities appear.

Search similar grants →

Eligibility Requirements

Patients who are uninsured, underinsured, or lack insurance coverage for EYLEA, are US residents, are enrolled in EYLEA4U, and show financial need. Eligible patients will be enrolled for up to 12 months.

Frequently Asked Questions

Who can apply for EYLEA4U Patient Assistance Program?

According to the current listing, eligibility includes: Patients who are uninsured, underinsured, or lack insurance coverage for EYLEA, are US residents, are enrolled in EYLEA4U, and show financial need. Eligible patients will be enrolled for up to 12 months. Confirm the full requirements in the official notice before applying.

Who funds EYLEA4U Patient Assistance Program?

EYLEA4U Patient Assistance Program is funded by Regeneron Pharmaceuticals. Verify program details on the funder's official page before applying.

How do I apply for EYLEA4U Patient Assistance Program?

Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.

Competitive Intelligence

Past winners and funding trends for this program

Full analysis

Funder Profile

Ready to start your proposal?

Granted drafts, reviews, and strengthens your grant application — saving weeks of work. Professional members win a grant in 12 months or get a full refund.

Browse More Grants

Backed by the Granted Guarantee

Similar Grants from Other Funders

National Cancer Institute (NCI)

VerifiedDeadline PassedBetween cycles

NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32 - Independent Clinical Trial Not Allowed)

NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.

VariesDeadline: Jun 12, 2025 (passed)